GlaxoSmithKline Pharmaceuticals Limited Stock NSE India S.E.
Equities
GLAXO
INE159A01016
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,034 INR | +0.55% | +2.93% | +6.95% |
05-09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
04-25 | GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology | RE |
Sales 2024 * | 33.65B 403M 549M | Sales 2025 * | 36.49B 437M 596M | Capitalization | 343B 4.11B 5.6B |
---|---|---|---|---|---|
Net income 2024 * | 6.06B 72.64M 98.99M | Net income 2025 * | 7.68B 91.99M 125M | EV / Sales 2024 * | 10.2 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 9.4 x |
P/E ratio 2024 * |
50.3
x | P/E ratio 2025 * |
44.7
x | Employees | 3,680 |
Yield 2024 * |
1.5% | Yield 2025 * |
1.56% | Free-Float | 24.42% |
1 day | +0.37% | ||
1 week | +2.93% | ||
Current month | -2.72% | ||
1 month | +7.51% | ||
3 months | -10.01% | ||
6 months | +28.75% | ||
Current year | +6.95% |
Managers | Title | Age | Since |
---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 54 | 22-11-30 |
Juby Chandy
DFI | Director of Finance/CFO | - | 22-03-31 |
Simrat Sohal
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Renu Sud Karnad
CHM | Chairman | 70 | 19-03-31 |
Manu Anand
BRD | Director/Board Member | 64 | 22-05-15 |
Director/Board Member | 74 | 15-03-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2,034 | +0.55% | 26 132 |
24-05-16 | 2,022 | +1.68% | 110,541 |
24-05-15 | 1,989 | -0.27% | 84,411 |
24-05-14 | 1,994 | -0.25% | 36,943 |
24-05-13 | 1,999 | +1.37% | 60,938 |
Delayed Quote NSE India S.E., May 17, 2024 at 01:47 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.36% | 694B | |
+30.77% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.77% | 239B | |
+9.13% | 209B | |
-3.97% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- GLAXO Stock
- GLAXO Stock